


- 13. (Amended) An antibody immunospecific for a polypeptide of claims 1.
- 14. (Amended) A pharmaceutical formulation which comprises a polypeptide according to claim 1 and a pharmaceutical acceptable carrier or excipient therefore.
- 16. (Amended) A pharmaceutical formulation of claim 14 comprising additional drugs wherein the additional drug is selected from aspirin, heparin or streptokinase or a combination thereof.
- 17. (Amended) Use of a polypeptide according to claim 1 for the manufacture of a medicament for the treatment of thromboembolic diseases.
- 18. (Amended) Use of a polypeptide according to claim 1 for coating artifical surfaces.
- 19. (Amended) Use of a polypeptide according to claim 1 for modifying intraocular lenses in order to lessen the thrombogenicity of the lens material.
- 20. (Amended) Use of a polypeptide according to claim 1 for contacting the lens surface
- 21. (Amended) Use of a polypeptide according to claim 1 for covalent crosslinking to modify said lens material.





23. (Amended) A method for identifying compounds which inhibit (antagonize) or agonize the polypeptide of claim 1 by observing the binding, or stimulation or inhibition of a functional response.